Glenmark Pharma clocks 2-fold jump in Q1 net profit at Rs 462 crore
The increase in profit came on the back of a strong demand for the company's medicines, while there was a marginal decline of 1.4 per cent in costs as well.
The increase in profit came on the back of a strong demand for the company's medicines, while there was a marginal decline of 1.4 per cent in costs as well.
Drug makers Cipla and Glenmark are recalling their products from the US market due to manufacturing issues.
